TOP > 外国特許検索 > PEPTIDE, POLYNUCLEOTIDE, VECTOR, TRANSFORMANT, NFκB INHIBITOR, AND THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH ACCELERATED NFκB ACTIVITY

PEPTIDE, POLYNUCLEOTIDE, VECTOR, TRANSFORMANT, NFκB INHIBITOR, AND THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH ACCELERATED NFκB ACTIVITY 新技術説明会

外国特許コード F160008892
整理番号 (S2015-0250-N0)
掲載日 2016年10月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP085286
国際公開番号 WO 2016098838
国際出願日 平成27年12月16日(2015.12.16)
国際公開日 平成28年6月23日(2016.6.23)
優先権データ
  • 特願2014-257827 (2014.12.19) JP
発明の名称 (英語) PEPTIDE, POLYNUCLEOTIDE, VECTOR, TRANSFORMANT, NFκB INHIBITOR, AND THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH ACCELERATED NFκB ACTIVITY 新技術説明会
発明の概要(英語) This peptide has an NFκB inhibitory effect and is any one of the following peptides: (a) a peptide comprising any amino acid sequence from SEQ ID NOs: 1-5; (b) a peptide having an NFκB inhibitory effect and comprising any amino acid sequence from SEQ ID NOs: 1-5, wherein one or a plurality of amino acid residues having been replaced, deleted and/or added; (c) a peptide having an NFκB inhibitory effect and comprising an amino acid sequence that is at least 80% homologous with any amino acid sequence from SEQ ID NOs: 1-5; (d) a peptide in which a cell-penetrating peptide is fused with any peptide selected from (a)-(c); and (e) a peptide in which a Met residue, a MetAla residue or an Ala residue is added to the N terminal of any peptide selected from (a)-(d).
従来技術、競合技術の概要(英語) BACKGROUND ART
A variety of cytokines in the inflammatory response and responsible for expression of the cell adhesion molecules are known. The inflammatory cytokines bind to a receptor corresponding to each of the various molecules in cells by phosphorylation occurs. This phosphorylation cascade may finally, nuclear transcription factor NFκB is activated, transcription of various inflammatory substances are believed to be promoted. In this way, activation of the inflammatory response is finally collected in the NFκB and, to effectively inhibit the activity of this NFκB as the drug, steroid drug is widely used.
Steroid drug is very potent effect on the other hand, can also cause serious side effects are known. For this reason, an alternative to steroid drug NFκB inhibitor has been desired.
Under such a background, the present inventors, facilitate transcription of the steroid drug in the same manner as NFκB directly inhibit activity can be on the other hand, corticosteroid hormones such as do not affect as novel peptides, found that the MTI-II(for example, see Patent Publication 4874798). Is MTI-II, 102 amino acid residues and a small peptide, having an inhibitory effect on NFκB portion in which, in the first to 75 from the first 32 amino acid sequence corresponding to the region thought to be an acidic amino acid. The present inventors, in the first to 75 from the first 36 amino acid peptide having the sequence from an arginine residue at C-terminus to a membrane-bound 8 peptide consisting of the peptides also referred to as (MPAID(MTI peptide anti-inflammatory drug) ) chemically synthesizing, was added to the cells HeLa, inhibited NFκB transcription promoting activity was confirmed (for example, 'Japan vitamin The Institute of 66 times of a meeting, vitamin, first 88 winding the first 4 signal, the first 260 page' and 'the first 87 times Japan raw Chemical Society convention, biochemical, first 86 winding Chemistry signal, the first 101 page' 4T13a - 04 ', the first page 136' 3P-006" reference). In addition, the peptide was applied to atopic dermatitis model animal administration of, an anti-inflammatory effect in vivo was confirmed in (for example, 'the first 87 times Japan raw Chemical Society convention, biochemical, first 86 winding Chemistry signal, the first 101 page' 4T13a - 04 ', the first page 136' 3P-006" reference).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE
  • 発明者(英語)
  • OKAMOTO, Kazuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ 技術移転のお問い合わせはMPO㈱でも結構です。TEL:044-979-1631 FAX:044-979-1632 Mail:info@mpoinc.Co.jp WEB:http://www.mpoinc.co.jp

PAGE TOP

close
close
close
close
close
close